Quick Answer
iBio, Inc. reported Cash and Equivalents of $8.58 million for fiscal year 2025.
iBio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.58M | -39.6% |
| 2024 | $14.21M | +230.4% |
| 2023 | $4.30M | -81.0% |
| 2022 | $22.68M | -70.7% |
| 2021 | $77.40M | +40.4% |
| 2020 | $55.11M | +1146.6% |
| 2019 | $4.42M | +0.0% |
| 2018 | $4.42M | -72.3% |
| 2017 | $15.93M | +0.0% |
| 2016 | $15.93M | +67.8% |
| 2015 | $9.49M | +164.5% |
| 2014 | $3.59M | -18.7% |
| 2013 | $4.41M | -21.5% |
| 2012 | $5.62M | +97.8% |
| 2011 | $2.84M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $28.67M | +308.7% | +2.0% |
| September 30, 2025 | $28.11M | +154.7% | +227.6% |
| June 30, 2025 | $8.58M | -39.6% | +73.1% |
| March 31, 2025 | $4.96M | -6.5% | -29.3% |
| December 31, 2024 | $7.01M | +151.6% | -36.4% |
| September 30, 2024 | $11.04M | +655.5% | -22.3% |
| June 30, 2024 | $14.21M | +230.4% | +168.0% |
| March 31, 2024 | $5.30M | -19.2% | +90.2% |
- iBio, Inc. showed a decrease of -39.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, iBio, Inc.’s cash and equivalents has grown by 201.9% (from $2.84 million to $8.58 million).
- The most recent figure is from iBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 5, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: